Short Report: Can We Use a Lower Dose of Liposomal Amphotericin B for the Treatment of Mucosal American Leishmaniasis?
Carregando...
Citações na Scopus
29
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER SOC TROP MED & HYGIENE
Autores
SANTOS, Carolina R.
Citação
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, v.85, n.5, p.818-819, 2011
Resumo
Liposomal amphotericin B has been used as an alternative treatment of mucosal leishmaniasis, but the optimal dose is not established. We retrospectively reviewed the clinical outcome of eight patients with mucosal leishmaniasis treated with liposomal amphotericin B. The mean total dose was 35 mg/kg (range 24-50 mg/kg), which resulted in the healing of all the lesions in all patients and no recurrences were observed during the follow-up period (mean 25 months; range 7-40 months).
Palavras-chave
Referências
- Amato VS, 2000, J ANTIMICROB CHEMOTH, V46, P341, DOI 10.1093/jac/46.2.341
- Amato VS, 2007, AM J TROP MED HYG, V77, P266
- Sundar S, 2011, LANCET, V377, P477, DOI 10.1016/S0140-6736(10)62050-8
- Bern C, 2006, CLIN INFECT DIS, V43, P917, DOI 10.1086/507530
- Amato VS, 2009, J EUR ACAD DERMATOL, V23, P1026, DOI 10.1111/j.1468-3083.2009.03238.x
- Sundar S, 2004, CLIN INFECT DIS, V38, P377, DOI 10.1086/380971
- Reithinger R, 2007, LANCET INFECT DIS, V7, P581, DOI 10.1016/S1473-3099(07)70209-8
- Camargo RA, 2010, AM J TROP MED HYG, V83, P515, DOI 10.4269/ajtmh.2010.10-0081
- Nonata R, 1997, Trans R Soc Trop Med Hyg, V91, P77
- Vogelsinger H, 2006, J ANTIMICROB CHEMOTH, V57, P1153, DOI 10.1093/jac/dk1141
- World Health Organization (WHO), 2010, M WHO EXP COMM CONTR